Zai Lab
Jiaqing Yi currently serves as a Senior Scientist at Zai Lab since September 2021, following a tenure as a Scientist II. Prior to this role, Jiaqing Yi was a Postdoctoral Fellow at UT Southwestern Medical Center from July 2016 to August 2021, conducting research on the H3K27me3 demethylase UTX, focusing on its mechanistic functions in normal brain development and medulloblastoma tumorigenesis. Noteworthy achievements include developing assays to study T cell migration and identifying UTX's tumor suppressor function through target gene research. Jiaqing Yi's earlier experience includes work as a Graduate Research Assistant at Virginia Tech, where research on appetite regulation in chickens led to significant contributions and over 10 publications, and at China Agricultural University, investigating feed supplements' effects on growth performance in monogastric animals. Educational credentials include a Ph.D. in Neuroendocrinology from Virginia Tech, an M.S. in Swine Nutrition from China Agricultural University, and a Bachelor's degree in Animal Science from Jiangnan University.
This person is not in any offices
Zai Lab
5 followers
Zai Lab Ltd is a biopharmaceutical company. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including in the fields of oncology, autoimmune and infectious diseases. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include three drug candidates with greater China rights and three drug candidates with global rights. The greater China rights drug candidates include Niraparib (ZL-2306), Omadacycline (ZL-2401) and ZL-2301. The global rights drug candidates include Fugan (ZL-3101), ZL-2302 and ZL-1101.